Shares of Shire PLC (NASDAQ:SHPG) saw strong trading volume on Thursday . 4,582,914 shares traded hands during mid-day trading, an increase of 299% from the previous session’s volume of 1,148,860 shares.The stock last traded at $144.63 and had previously closed at $140.03.

A number of equities research analysts have issued reports on the stock. Royal Bank Of Canada reissued a “buy” rating on shares of Shire PLC in a report on Thursday. Cantor Fitzgerald set a $222.00 price target on shares of Shire PLC and gave the stock a “buy” rating in a report on Thursday. Liberum Capital raised shares of Shire PLC from a “hold” rating to a “buy” rating in a report on Tuesday. FBR & Co reissued a “buy” rating and issued a $201.00 price target on shares of Shire PLC in a report on Monday, October 30th. Finally, Cowen and Company set a $225.00 price target on shares of Shire PLC and gave the stock a “buy” rating in a report on Sunday, October 29th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and eleven have issued a buy rating to the company. The company has an average rating of “Buy” and an average target price of $212.18.

The stock has a market capitalization of $43,610.00, a PE ratio of 9.58, a PEG ratio of 0.77 and a beta of 1.60. The company has a current ratio of 0.98, a quick ratio of 0.52 and a debt-to-equity ratio of 0.55.

Shire PLC (NASDAQ:SHPG) last issued its quarterly earnings results on Friday, October 27th. The biopharmaceutical company reported $3.81 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.64 by $0.17. Shire PLC had a net margin of 10.95% and a return on equity of 14.41%. The company had revenue of $3.70 billion during the quarter. During the same period last year, the business earned $3.17 earnings per share. The company’s revenue was up 7.1% on a year-over-year basis. equities analysts anticipate that Shire PLC will post 15 EPS for the current fiscal year.

A number of hedge funds and other institutional investors have recently modified their holdings of SHPG. Harding Loevner LP lifted its position in Shire PLC by 18,894.4% during the 3rd quarter. Harding Loevner LP now owns 127,537,052 shares of the biopharmaceutical company’s stock valued at $20,354,000 after acquiring an additional 126,865,607 shares during the period. Janus Henderson Group PLC raised its holdings in Shire PLC by 22,560.3% in the second quarter. Janus Henderson Group PLC now owns 1,286,881 shares of the biopharmaceutical company’s stock worth $212,683,000 after buying an additional 1,281,202 shares during the last quarter. Third Point LLC purchased a new position in Shire PLC in the third quarter worth about $183,768,000. Glenview Capital Management LLC raised its holdings in Shire PLC by 69.7% in the second quarter. Glenview Capital Management LLC now owns 1,722,977 shares of the biopharmaceutical company’s stock worth $284,756,000 after buying an additional 707,500 shares during the last quarter. Finally, Sterling Capital Management LLC raised its holdings in Shire PLC by 26,182.4% in the third quarter. Sterling Capital Management LLC now owns 474,397 shares of the biopharmaceutical company’s stock worth $72,649,000 after buying an additional 472,592 shares during the last quarter. 18.27% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION WARNING: “Shire PLC (SHPG) Sees Large Volume Increase” was posted by Watch List News and is owned by of Watch List News. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and international copyright & trademark legislation. The correct version of this report can be read at https://www.watchlistnews.com/shire-plc-shpg-sees-large-volume-increase/1708200.html.

Shire PLC Company Profile

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.

Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.